
Promising Phase 1 Results for Traws Pharma’s COVID Treatment Candidate
NEWTOWN, PA — Traws Pharma, Inc. (NASDAQ: TRAW) has reported encouraging topline results from its Phase 1 trial of ratutrelvir, an oral inhibitor designed to combat COVID-19. The trial demonstrated favorable …
Promising Phase 1 Results for Traws Pharma’s COVID Treatment Candidate Read More